New study presented on Lactobacillus reuteri Protectis
(Thomson Reuters ONE) -
Lactobacillus reuteri Protectis reduced crying time in infants with colic
After only one week of supplementation the reduction in daily crying time was
74 % among the infants supplemented by L. reuteri Protectis compared to 38 % in
the placebo group. At the end of the study there was a significant difference
between the two groups. - These results are in line with previous studies on
colics and confirm the benefit of L. reuteri in colicky infants, says Doctor
Francesco Savino, Department of Paediatrics, Regina Margherita Children's
Hospital, University of Turin, Italy.
In this double blind, placebo controlled study 50 infants with confirmed
infantile colic were randomly assigned to two treatments: L. reuteri Protectis
drops 10^8 CFU per day or placebo for 21 consecutive days.
The primary outcome was a reduction in average crying time to less than three
hours per day, which is the limit of colic, by day 21. On day 21, 84 % of the L.
reuteri Protectis supplemented infants had resolved their colic (dropped to less
than three hours of crying), a significantly higher number compared to 43% in
the placebo group (p<0.05).
At the time of inclusion the median crying time per day was 370 minutes in the
probiotic group and 300 minutes in the placebo group. On day seven the crying
time had been reduced by 74 %, to 95 minutes, in the L. reuteri Protectis group
and to 185 minutes in the placebo group (p=0.082). At the end of the study there
was a significant difference in median daily crying time between the groups, 35
minutes in the L. reuteri Protectis group versus 90 minutes in the placebo group
(p<0.05).
The proportion of infants responding to the supplementation, defined as a 50 %
or greater reduction in median crying time, was significantly greater in the L.
reuteri Protectis group compared to the placebo group at day 7, 14 and 21 of the
study.
- The data with L. reuteri are convincing and confirm, in a placebo-controlled
study, our earlier data with this probiotic. We believe these results will have
an impact on the treatment of infants with colic, says Doctor Savino.
The study was presented on the Annual Meeting of ESPGHAN in Istanbul on the
10th of June 2010.
For additional information contact:
Francesco Savino, MD, PhD, Dept Paediatrics, Regina Margherita Children's
Hospital, Turin: +39 335 801 8901 (mobile) or francesco.savino(at)unito.itEamonn
Connolly, Senior Vice President Research, BioGaia AB: +46 8 555 293 00 or
ec(at)biogaia.se
Peter Rothschild, President, BioGaia AB: +46 8 555 293 00 or pr(at)biogaia.se
Latest press releases from BioGaia:
2010-06-03 BioGaia signs agreement for China
2010-05-26 Change in number of shares in BioGaia
2010-05-10 New study published: Lactobacillus reuteri Protectis reduced
gastrointestinal symptoms and hospital stay in premature newborns
[HUG#1422891]
BioGaiapressrelease10June2010(pdf): http://hugin.info/86913/R/1422891/371894.pdf
Unternehmensinformation / Kurzprofil:
Datum: 10.06.2010 - 09:50 Uhr
Sprache: Deutsch
News-ID 22212
Anzahl Zeichen: 0
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 259 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"New study presented on Lactobacillus reuteri Protectis"
steht unter der journalistisch-redaktionellen Verantwortung von
BioGaia AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
